ArticleInternational journal of cancer2020

Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.

Christopher L Heidler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.